Latest Information Update: 23 Nov 1995
At a glance
- Originator Novartis
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 23 Nov 1995 Discontinued-Preclinical for Inflammation in Switzerland (Unknown route)